Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA Exploration
Authors:
- Eriseld KrasniqiEKEriseld Krasniqi
- Frauke GoemanFGFrauke Goeman
- Claudio PulitoClaudio Pulito
- Alina Catalina PalcauAPAlina Catalina Palcau
- Ludovica CiuffredaLCLudovica Ciuffreda
- Francesca Sofia Di LisaFLFrancesca Sofia Di Lisa
- Lorena FilomenoLFLorena Filomeno
- Maddalena BarbaMBMaddalena Barba
- Laura PizzutiLPLaura Pizzuti
- Federico CappuzzoFederico Cappuzzo
- Giuseppe SanguinetiGSGiuseppe Sanguineti
- Marcello Maugeri-SaccàMMMarcello Maugeri-Saccà
Open Access
- 22 November 2022
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (23) , 14534
Abstract
New evidence on the impact of dysregulation of the CDK4/6 pathway on breast cancer (BC) cell proliferation has led to the development of selective CDK4/6 inhibitors, which have radically changed the management of advanced BC. Despite the improved outcomes obtained by CDK4/6 inhibitors, approximately 10% of tumors show primary resistance, whereas acquired resistance appears to be an almost ubiquitous occurrence, leading to treatment failure. The identification of differentially expressed genes or genomic mutational signatures able to predict sensitivity or resistance to CDK4/6 inhibitors is critical for medical decision making and for avoiding or counteracting primary or acquired resistance against CDK4/6 inhibitors. In this review, we summarize the main mechanisms of resistance to CDK4/6 inhibitors, focusing on those associated with potentially relevant biomarkers that could predict patients’ response/resistance to treatment. Recent advances in biomarker identification are discussed, including the potential use of liquid biopsy for BC management and the role of multiple microRNAs as molecular predictors of cancer cell sensitivity and resistance to CDK4/6 inhibitors.Keywords
Funding Information
- Ricerca Corrente 2022 from the Italian Ministry of Health
This publication has 100 references indexed in Scilit:
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer CellsMolecular Cancer Therapeutics, 2012
- The retinoblastoma family of proteins and their regulatory functions in the mammalian cell division cycleCell Division, 2012
- Cyclin D as a therapeutic target in cancerNature Reviews Cancer, 2011
- Analysis of MiR-195 and MiR-497 Expression, Regulation and Role in Breast CancerClinical Cancer Research, 2011
- DNA damage and breast cancerWorld Journal of Clinical Oncology, 2011
- PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitroBreast Cancer Research, 2009
- The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomasBreast Cancer Research, 2008
- Oncomirs — microRNAs with a role in cancerNature Reviews Cancer, 2006
- MicroRNAsCell, 2004